Friday, 14 February 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 14 February 2025
News

No backing down after TGA snub

Posted 30 January 2025 AM 

Despite being snubbed by the TGA and consequently pulling a co-dependent reimbursement submission for Leqembi, Eisai has confirmed that work is well underway to make the Alzheimer's disease (AD) treatment available in Australia.

While Eisai and Biogen are co-commercialising and co-promoting Leqembi, also known as lecanemab, Eisai serves as the head of Leqembi development and regulatory submissions globally. The Japanese firm also has the final decision-making authority.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (14)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (4)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.